{"title":"补充维生素 D 对治疗 SARS-COV-2 的潜在疗效:系统综述/meta 分析","authors":"Lobna Mohamed Bahaa El-Din, Mohamed Nazmy Farres, G. Amin, Mohamed Farouk Allam, Rasha Samir","doi":"10.54034/mic.e1964","DOIUrl":null,"url":null,"abstract":"Background: vitamin D deficiency has long been associated with decreased immune function and can lead to viral infections. Studies have shown that vitamin D deficiency is associated with an increased risk of COVID-19 infection. However, it is unclear whether treatment with vitamin D can reduce the associated risk of COVID-19 infection. Objective: the current meta-analysis aimed to determine whether vitamin D supplementation had a positive or negative impact on COVID-19 patients. Materials and methods: for this systematic review and meta-analysis, we searched the following databases; CENTERAL, Medline (PubMed), Web of Science, EMBASE and Egyptian Knowledge Bank (EKB, for studies published till February 20, 2022, using key terms. Besides, reference lists of relevant studies were identified. We considered randomized trials (RCTs) and cohort studies as potentially eligible when patients were tested for SARS-CoV-2 infection and received vitamin D supplementation versus a placebo or standard-of-care control. We identified a total of 718 articles, of which 4 RCTs and 3 cohort studies which meet eligible criteria. The seven studies included in our meta-analysis involved 1238 subjects. We considered 7 outcomes to be measured in our meta-analysis which are duration of COVID-19 illness till recovery, need for O2 therapy, need for ICU admission, need for artificial ventilation, fatal prognosis, time to negative PCR and need for hospitalization. Results: vitamin D supplement decreased the period of hospital stay in SARS-CoV2 positive patients. There was no clear protective effect of vitamin D supplementation on the need for oxygen therapy. There was no reduction on need for ICU admission in SARS-CoV2 patients treated with vitamin D supplementation. There was a significant reduction on need for artificial ventilation in patients treated with vitamin D supplementation. Our meta-analysis showed that there is no reduction on fatal prognosis in patients treated with vitamin D supplementation. Only one RCT evaluated time to negative PCR; this study was conducted in India and showed that vitamin D supplementation helped to achieve SARS-CoV-2 RNA negativity in greater proportion of COVID-19 patients with vitamin D supplementation. Conclusion: administration of vitamin D after diagnosis of SARS-CoV-2 infection reduces the period of hospital stay and also reduces the need for artificial ventilation.","PeriodicalId":486828,"journal":{"name":"Microbes, infection and chemotherapy","volume":" 20","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The potential therapeutic effect of vitamin D supplementation for management of SARS-COV-2: a systematic review/meta-analysis\",\"authors\":\"Lobna Mohamed Bahaa El-Din, Mohamed Nazmy Farres, G. Amin, Mohamed Farouk Allam, Rasha Samir\",\"doi\":\"10.54034/mic.e1964\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: vitamin D deficiency has long been associated with decreased immune function and can lead to viral infections. Studies have shown that vitamin D deficiency is associated with an increased risk of COVID-19 infection. However, it is unclear whether treatment with vitamin D can reduce the associated risk of COVID-19 infection. Objective: the current meta-analysis aimed to determine whether vitamin D supplementation had a positive or negative impact on COVID-19 patients. Materials and methods: for this systematic review and meta-analysis, we searched the following databases; CENTERAL, Medline (PubMed), Web of Science, EMBASE and Egyptian Knowledge Bank (EKB, for studies published till February 20, 2022, using key terms. Besides, reference lists of relevant studies were identified. We considered randomized trials (RCTs) and cohort studies as potentially eligible when patients were tested for SARS-CoV-2 infection and received vitamin D supplementation versus a placebo or standard-of-care control. We identified a total of 718 articles, of which 4 RCTs and 3 cohort studies which meet eligible criteria. The seven studies included in our meta-analysis involved 1238 subjects. We considered 7 outcomes to be measured in our meta-analysis which are duration of COVID-19 illness till recovery, need for O2 therapy, need for ICU admission, need for artificial ventilation, fatal prognosis, time to negative PCR and need for hospitalization. Results: vitamin D supplement decreased the period of hospital stay in SARS-CoV2 positive patients. There was no clear protective effect of vitamin D supplementation on the need for oxygen therapy. There was no reduction on need for ICU admission in SARS-CoV2 patients treated with vitamin D supplementation. There was a significant reduction on need for artificial ventilation in patients treated with vitamin D supplementation. Our meta-analysis showed that there is no reduction on fatal prognosis in patients treated with vitamin D supplementation. Only one RCT evaluated time to negative PCR; this study was conducted in India and showed that vitamin D supplementation helped to achieve SARS-CoV-2 RNA negativity in greater proportion of COVID-19 patients with vitamin D supplementation. Conclusion: administration of vitamin D after diagnosis of SARS-CoV-2 infection reduces the period of hospital stay and also reduces the need for artificial ventilation.\",\"PeriodicalId\":486828,\"journal\":{\"name\":\"Microbes, infection and chemotherapy\",\"volume\":\" 20\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-06-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Microbes, infection and chemotherapy\",\"FirstCategoryId\":\"0\",\"ListUrlMain\":\"https://doi.org/10.54034/mic.e1964\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Microbes, infection and chemotherapy","FirstCategoryId":"0","ListUrlMain":"https://doi.org/10.54034/mic.e1964","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:长期以来,维生素 D 缺乏与免疫功能下降有关,并可能导致病毒感染。研究表明,维生素 D 缺乏与 COVID-19 感染风险增加有关。然而,目前还不清楚维生素 D 治疗是否能降低 COVID-19 感染的相关风险。目的:本荟萃分析旨在确定维生素 D 补充剂对 COVID-19 患者的影响是积极的还是消极的。材料和方法:为了进行此次系统综述和荟萃分析,我们使用关键术语检索了以下数据库:CENTERAL、Medline (PubMed)、Web of Science、EMBASE 和 Egyptian Knowledge Bank (EKB,检索截至 2022 年 2 月 20 日发表的研究。此外,我们还查找了相关研究的参考文献目录。我们将随机试验(RCT)和队列研究视为可能符合条件的研究,只要患者接受了 SARS-CoV-2 感染检测,并接受了维生素 D 补充剂与安慰剂或标准护理对照。我们共发现了 718 篇文章,其中 4 项 RCT 和 3 项队列研究符合合格标准。纳入荟萃分析的 7 项研究涉及 1238 名受试者。我们在荟萃分析中考虑了 7 项结果,即 COVID-19 病程至痊愈的持续时间、氧气治疗需求、入住重症监护室的需求、人工通气需求、致命预后、PCR 阴性时间和住院需求。结果:补充维生素 D 缩短了 SARS-CoV2 阳性患者的住院时间。补充维生素 D 对氧治疗的需求没有明显的保护作用。接受维生素 D 补充剂治疗的 SARS-CoV2 患者入住重症监护室的需求没有减少。补充维生素 D 后,患者对人工通气的需求明显减少。我们的荟萃分析表明,补充维生素 D 不会减少患者的死亡预后。只有一项研究对 PCR 阴性的时间进行了评估;这项研究在印度进行,结果显示补充维生素 D 有助于使更多的 COVID-19 患者达到 SARS-CoV-2 RNA 阴性。结论:在确诊 SARS-CoV-2 感染后服用维生素 D 可缩短住院时间,减少人工通气的需要。
The potential therapeutic effect of vitamin D supplementation for management of SARS-COV-2: a systematic review/meta-analysis
Background: vitamin D deficiency has long been associated with decreased immune function and can lead to viral infections. Studies have shown that vitamin D deficiency is associated with an increased risk of COVID-19 infection. However, it is unclear whether treatment with vitamin D can reduce the associated risk of COVID-19 infection. Objective: the current meta-analysis aimed to determine whether vitamin D supplementation had a positive or negative impact on COVID-19 patients. Materials and methods: for this systematic review and meta-analysis, we searched the following databases; CENTERAL, Medline (PubMed), Web of Science, EMBASE and Egyptian Knowledge Bank (EKB, for studies published till February 20, 2022, using key terms. Besides, reference lists of relevant studies were identified. We considered randomized trials (RCTs) and cohort studies as potentially eligible when patients were tested for SARS-CoV-2 infection and received vitamin D supplementation versus a placebo or standard-of-care control. We identified a total of 718 articles, of which 4 RCTs and 3 cohort studies which meet eligible criteria. The seven studies included in our meta-analysis involved 1238 subjects. We considered 7 outcomes to be measured in our meta-analysis which are duration of COVID-19 illness till recovery, need for O2 therapy, need for ICU admission, need for artificial ventilation, fatal prognosis, time to negative PCR and need for hospitalization. Results: vitamin D supplement decreased the period of hospital stay in SARS-CoV2 positive patients. There was no clear protective effect of vitamin D supplementation on the need for oxygen therapy. There was no reduction on need for ICU admission in SARS-CoV2 patients treated with vitamin D supplementation. There was a significant reduction on need for artificial ventilation in patients treated with vitamin D supplementation. Our meta-analysis showed that there is no reduction on fatal prognosis in patients treated with vitamin D supplementation. Only one RCT evaluated time to negative PCR; this study was conducted in India and showed that vitamin D supplementation helped to achieve SARS-CoV-2 RNA negativity in greater proportion of COVID-19 patients with vitamin D supplementation. Conclusion: administration of vitamin D after diagnosis of SARS-CoV-2 infection reduces the period of hospital stay and also reduces the need for artificial ventilation.